medigraphic.com
ISSN 1561-302X (Print)

2021, Number 3

<< Back Next >>

Rev cubana med 2021; 60 (3)

Prognostic factors for autologous transplantation in patients with Hodgkin Lymphoma

Hernández CC, Carnot UJ, Muñío PJ, García GA, Ríos JO, Rodríguez FY

Language: Spanish
References: 19
Page: 1-13
PDF size: 403.78 Kb.


ABSTRACT

Introduction: Autologous hematopoietic stem cell transplantation is a therapy used in certain situations to patients with Hodgkin's Lymphoma.
Objective: To evaluate the influence of selected prognostic factors on the results of autologous hematopoietic stem cell transplantation in patients with Hodgkin's Lymphoma.
Methods: A retrospective study of 57 patients with a diagnosis of Hodgkin Lymphoma transplanted at Hermanos Ameijeiras Clinical Surgical Hospital from 1991 to 2018 was carried out. The influence of several unfavorable factors was evaluated according to univariate and multivariate disease-free survival at five years.
Results: A lower disease-free survival was found for all groups with unfavorable categories. Univariate analysis indicated that receiving three or more previous lines of treatment increased the probability of relapse on average 3.48 times. In the multiple evaluation, the probability of relapse was significantly increased by the existence of active disease at the time of transplantation (p = 0.023) and by not receiving radiotherapy in the conditioning treatment (p = 0.010).
Conclusions: The importance of knowing the unfavorable factors was established. It was of noteworthy importance to avoid active disease at transplantation and to carry out a correct evaluation of risks and benefits regarding the possible inclusion of radiotherapy in the conditioning treatment.


REFERENCES

  1. Broccoli A, Zinzani PL. The role of transplantation in Hodgkin lymphoma. Br J Haematol. 2019;184(1):93-104. https://doi.org/10.1111/bjh.15639

  2. Vassilakopoulos TP, Asimakopoulos JV, Konstantopoulos K, Angelopoulou MK. Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies. Ther Adv Hematol. 2020;11:1-31. Disponible en: https://doi.org/10.1177/2040620720902911

  3. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE, et al. Bone-marrow transplantation. N Engl J Med. 1975[acceso: 26/11/2020];292(16):832-902. Disponible en: Disponible en: https://www.nejm.org/doi/10.1056/NEJM197504172921605?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

  4. Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: Long-term outcome in the first 100 patients treated in Vancouver. Blood. 2005;106(4):1473-8. Disponible en: https://doi.org/10.1182/blood-2004-12-4689

  5. Bierman PJ, Lynch JC, Bociek RG, Whalen VL, Kessinger A, Vose JM, et al. The International Prognostic Factors Project score for advanced Hodgkin’s disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol. 2002;13(9):1370-7. Disponible en: https://doi.org/10.1093/annonc/mdf228

  6. Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2002[acceso: 26/11/2020];20(1):221-30. Disponible en: Disponible en: https://ascopubs.org/doi/10.1200/JCO.2002.20.1.221?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

  7. Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol. 2005;16(4):625-33. Disponible en: https://doi.org/10.1093/annonc/mdi119

  8. Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model. Blood. 2001;97(3):616-23. Disponible en: https://doi.org/10.1182/blood.V97.3.616

  9. Chan FC, Mottok A, Gerrie AS, Power M, Nijland M, Diepstra A, et al. Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma. J Clin Oncol. 2017;35(32):3722-33. Disponible en: http://ascopubs.org/doi/full/10.1200/JCO.2017.72.7925

  10. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-90. Disponible en: https://doi.org/10.1182/blood-2016-01-643569

  11. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971[acceso: 26/11/2020];31(11):1860-1. Disponible en: Disponible en: https://cancerres.aacrjournals.org/content/31/11/1860.long

  12. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am. 2007;21(5):841-54. Disponible en: https:// doi.org/10.1016/j.hoc.2007.06.011

  13. Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J Clin Oncol. 2003[acceso: 26/11/2020];21(4):607-14. Disponible en: Disponible en: https://ascopubs.org/doi/10.1200/JCO.2003.12.086?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

  14. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003[acceso: 26/11/2020];348(24):2386-95. Disponible en: Disponible en: https://www.nejm.org/doi/10.1056/NEJMoa022473?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0www.ncbi.nlm.nih.gov

  15. Goel MK, Khanna P, Kishore J. Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res. 2010[acceso: 26/11/2020];1(4):274-8. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059453/

  16. Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta JJ, García-Conde J, et al. Autologous stem-cell transplantation for Hodgkin’s disease: Results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group. J Clin Oncol. 2001;19(5):1395-404. Disponible en: https://ascopubs.org/doi/10.1200/JCO.2001.19.5.1395?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

  17. Fatobene G, Linardi CDCG, Moreira F, GMF Targueta, Santos FM, Velásquez RD. Reassessment of risk factors and long-term results of autologous stem cell transplantation in relapsed and refractory classical Hodgkin lymphoma. Hematol Oncol. 2019;37(3):310-3. Disponible en: https://doi.org/10.1002/hon.2604

  18. LaCasce AS. Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease. Hematol Oncol. 2019;37(1):87-91. https://doi.org/10.1002/hon.2589

  19. Bentolila G, Pavlovsky A. Relapse or refractory Hodgkin lymphoma: determining risk of relapse or progression after autologous stem-cell transplantation. Leuk Lymphoma. 2020;61(7):1548-54. Disponible en: https://doi.org/10.1080/10428194.2020.1732959




2020     |     www.medigraphic.com